Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine
- PMID: 1642562
- DOI: 10.1007/BF01309630
Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine
Abstract
The effect of immunisation with an HSV-1 antigen preparation (containing at least 6 viral glycoproteins) on primary infection with HSV and the establishment of latency, was assessed in two mouse models (involving either skin or corneal challenge with virus). The vaccine preparation, given either with Freund's complete adjuvant or aluminium hydroxide gel or in the form of immunostimulating complexes (ISCOMS), induced high ELISA antibody responses (highest with HSV as the ISCOM preparation) and low levels of neutralising antibody. In both models, immunisation with the HSV ISCOM preparation significantly reduced the incidence of zosteriform spread of virus and the severity of disease and, in some cases, the incidence of latent infection in sensory ganglia. In the eye model it was possible to show that immunisation with the HSV ISCOMS restricted the establishment of latency almost entirely to the ophthalmic part of the trigeminal ganglion. Protection from establishment of latency correlated with prechallenge antibody levels.
Similar articles
-
Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.Vaccine. 2000 Apr 14;18(20):2083-94. doi: 10.1016/s0264-410x(99)00567-8. Vaccine. 2000. PMID: 10715522
-
A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection.Antiviral Res. 2001 Feb;49(2):83-99. doi: 10.1016/s0166-3542(00)00142-x. Antiviral Res. 2001. PMID: 11248361
-
Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.J Gen Virol. 1989 Aug;70 ( Pt 8):2149-55. doi: 10.1099/0022-1317-70-8-2149. J Gen Virol. 1989. PMID: 2769234
-
Current status and potential application of ISCOMs in veterinary medicine.Adv Drug Deliv Rev. 2004 Jun 23;56(10):1367-82. doi: 10.1016/j.addr.2004.02.004. Adv Drug Deliv Rev. 2004. PMID: 15191787 Review.
-
Vaccination against herpesvirus, fiction or reality?Scand J Infect Dis Suppl. 1991;80:110-8. Scand J Infect Dis Suppl. 1991. PMID: 1666442 Review.
Cited by
-
Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread.J Virol. 2001 Jun;75(11):5069-75. doi: 10.1128/JVI.75.11.5069-5075.2001. J Virol. 2001. PMID: 11333887 Free PMC article.
-
Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.Arch Virol. 1995;140(6):1015-31. doi: 10.1007/BF01315412. Arch Virol. 1995. PMID: 7611875
-
Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.J Virol. 2003 Jun;77(12):6692-9. doi: 10.1128/jvi.77.12.6692-6699.2003. J Virol. 2003. PMID: 12767989 Free PMC article.
-
Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.J Virol. 2001 Feb;75(4):1664-71. doi: 10.1128/JVI.75.4.1664-1671.2001. J Virol. 2001. PMID: 11160664 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Molecular Biology Databases